A team of Xiyuan Hospital researchers reveal circadian disruption (CD) as a key driver of cardiovascular disease (CVD) multi-organ comorbidities. Caused by sleep/eating irregularities and shift work, CD disturbs SCN-controlled peripheral rhythms, triggering damage via autonomic/metabolic imbalance and gut dysbiosis, with bidirectional harm between CD and end-organ damage. CD has distinct pathological effects on cardio-cerebral, cardio-hepatic and cardio-renal comorbidities. Chronotherapies and clock-targeted drugs show promise. The study advocates personalized chronomedicine and temporal-dimension integration for network-based CVD management.

The HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur on May 10.

YBhg. Datuk Dr. Nor Fariza Binti Ngah, Deputy Director-General of Health (Research and Technical Support) at the Ministry of Health of Malaysia, and Hou Yong, General Manager of BGI Genomics, joined leading experts to discuss urgent priorities in rare disease diagnosis, genomics, and public health response.

A WashU Medicine-led clinical trial conducted at Siteman Cancer Center has found that a personalized vaccine to treat glioblastoma is safe and could potentially improve outcomes. 

A clinical trial, led by researchers at Washington University School of Medicine in St. Louis, shows that a stem cell transplant in which the donor cells have been genetically engineered to remove a particular protein helps prevent toxic side effects and potentially improves the effectiveness of therapies given after a transplant to help prevent cancer recurrence.

An international research group recently demonstrated that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now, under the leadership of scientists at the University of Zurich and Balgrist University Hospital, the group has revealed for the first time how the therapy actually works. With a boost from this novel antibody, new nerve fibers form functional connections once again, allowing patients to become more independent.

New research, from King’s College London and the University of Porto, has mapped the histamine system in the brain. Histamine, a molecule more commonly associated with allergies, also plays a separate but poorly understood role in brain function. This study addresses this gap, building the first multiscale map of the histamine system which spans from genetics to behaviour and related mental health conditions. 

We feel more anxious when facing uncertain or unpredictable situations, but for those who score higher on autistic traits, this anxiety tends to be stronger. Published in Scientific Reports, a new study suggests uncertainty-driven anxiety plays a role in how people manage their emotions. Researchers at Nagoya University in Japan found evidence that people with higher autistic traits may try to cope with uncertainty by labeling their feelings. Offering support, such as the right words for what they feel, could play a role in managing anxiety.

Targeted protein degradation has become one of the most promising strategies in modern drug discovery, enabling scientists to eliminate disease-causing proteins instead of merely blocking them. Now, researchers at CeMM, AITHYRA (both Institutes of the Austrian Academy of Sciences), and CeTPD have discovered that a single small molecule can recruit not one, but two independent protein disposal systems at the same time. This dual mechanism introduces a built-in redundancy that could make future degrader therapies more robust and less vulnerable to resistance. The findings, reported in Nature Chemical Biology (DOI: 10.1038/s41589-026-02224-y), expand the design principles of targeted protein degradation and open new avenues for more resilient medicines.